Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 30Leukemia 15Burkitt Lymphoma 10Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 4Lymphoma, Extranodal NK-T-Cell 4Leukemia, Biphenotypic, Acute 4Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Lymphohistiocytosis, Hemophagocytic 2Epstein-Barr Virus Infections 2Down Syndrome 2Neoplasms 1Lymphoproliferative Disorders 1Lymphoma 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Immunoproliferative Disorders 1Drug-Related Side Effects and Adverse Reactions 1Blast Crisis 1

Interventions

Rituximab 2Epoetin Alfa 2Early Intervention, Educational 2Dexamethasone 2Darbepoetin alfa 2Bortezomib 2ponatinib 1pegaspargase 1isatuximab 1ibrutinib 1ibritumomab tiuxetan 1ferrous sulfate 1ferric gluconate 1ferric carboxymaltose 1cirmtuzumab 1blinatumomab 1asparaginase erwinia chrysanthemi recombinant 1acalabrutinib 1Vorinostat 1Vincristine 1Sucrose 1Prednisone 1Methotrexate 1Melphalan 1Lenalidomide 1Imatinib Mesylate 1Ifosfamide 1Etoposide 1Doxorubicin 1Daunorubicin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Lymphoproliferative Disorders × pegaspargase × Clear all
NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Amgen

Phase 3 Completed
111 enrolled 23 charts 1 FDA
LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡